We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced the launch of a new assay to meet the needs of pharma companies, CROs, clinicians and research scientists working on multiple myeloma (MM).
Menarini Silicon Biosystems, the pioneer of liquid biopsy technology, today announced the publication of a research study providing support for the reliability of using circulating tumor cell (CTC) count to guide frontline therapy choice for patients ...